Edward Lanphier, Special Advisor to the President and CEO
With more than 30 years of experience in the biotechnology industry, Edward Lanphier is a globally recognized leader in his field. Throughout his professional career, Mr. Lanphier has been on the forefront of health innovations and therapeutic solutions.
Mr. Lanphier was appointed Special Advisor to the President and CEO of the Buck Institute in November 2016, and has served on the Board of Trustees since 2012.
In 1995, Mr. Lanphier founded Sangamo BioSciences, a clinical stage biopharmaceutical company that researches and conducts gene therapy and genome editing. Since Sangamo’s start in 1995, Mr. Lanphier served as President and Chief Executive Office until June 2016, and currently serves as Chairman of Sangamo’s Board of Directors. Mr. Lanphier previously served as Chairman on the Board of Directors of the Alliance for Regenerative Medicine, and is a member of the Board of Directors for the Biotechnology Institute and on the Dean’s Advisory Board for the University of Michigan, School of Public Health.
Mr. Lanphier has significant nonprofit experience with globally focused research and advocacy organizations. Before founding Sangamo, he held management positions at some of the pharmaceutical and biotechnology industry’s most respected companies, including Eli Lilly, Synergen, and Somatix.
Mr. Lanphier received a B.A. in Biochemistry from Knox College.